Vol. 3, 653-659, May 1997 Clinical Cancer Research 653

Postsurgical Oral Administration of Uracil and Tegafur Inhibits Progression of Micrometastasis of Human Cells in Nude Mice1

Junichi Kurebayashi,2 Mamoru NUkatSUka, inhibited by the administration of either dose of UFT. In Akio Fujioka, Hitoshi Saito, Setsuo Takeda, conclusion, this new pOStSUrgIcal metastasis model may be useful for evaluating the efficacy of agents used in the post- Norio Unemi, Hiroyuki Fukumori, operative adjuvant setting. UFI may be an effective drug for MasafUmi Kurosumi, Hiroshi Sonoo, Inhibiting the progression of mlcrometastasis after surgery. and Robert B. Dickson Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701-01, Japan [J. K., INTRODUCTION H. So.]; Taiho Pharmaceutical Co. Ltd., Tokyo 101, Japan EM. N., The efficacy of postoperative adjuvant A. F., H. Sa., S. T., N. U., H. F.]; Department of Pathology, Saitama and/or endocrine therapy in reducing the mortality of breast Cancer Center, Saitama 362, Japan [M. K.]; and Lombardi Cancer cancer patients has been widely accepted on the basis of the data Center, Georgetown University Medical Center, Washington, DC 20007 [R. B. D.] from many prospective clinical trials (1-3). These agentsused in the postoperative adjuvant setting have already been proven to be effective in the treatment of advanced breast cancer. The ABSTRACT antitumor activity of these agents is believed to be involved in We recently established a metastasis model In nude inhibition of the progression of micrometastasis, which may mice using the MKL-4 cell line, a contransfectant of the already exist at the time of surgery. However, evaluation of such MCF-7 human breast cancer cell line withfgf-4 and lacZ in an inhibitory effect in animal experimental models is hard which micrometastases in several organs can be quantita- because of the difficulty in quantitatively measuring the degree lively observed. First, to develop a new postsurgical metas- of micrometastasis in animal organs. Sledge et a! (4) recently tasis model, we investigated the timing of occurrence of introduced a new postoperative metastasis model in nude mice micrometastasis and the influence of tumor removal on the using a human breast cancer cell line, MDA-MB-435 (5). They progression of micrometastasis in this model. Micrometas- reported that a matrix metalloproteinase inhibitor, Batimastat, tases into lymph nodes and lungs were detected 3 weeks inhibited the regrowth of primary tumors and reduced the num- after the cell injections. Tumor removal 3 weeks after the ber and volume of macroscopic lung metastases after the pri- injections significantly enhanced the progression of micro- mary tumor removal. However, neither any promoting effect of metastasis into lymph nodes and bone. Second, to study the the primary tumor removal nor any inhibitory effect of the effect of a mixed compound, UVl (a molar ratio of uradil: metalloproteinase inhibitor on the progression of micrometasta- tegafur of 4:1), which has been widely used in the postsur- sis has yet been described. gical adjuvant setting in Japan, 15 or 20 mg/kg UFF were We recently established a new metastasis model in nude administered p.o. for 4 weeks to tumor-bearing mice or to mice using the MKL-4 cell line, a cotransfectant of the MCF-7 mice in which transplanted tumors were resected 3 weeks human breast carcinoma cell line with a potent angiogenic factor after the injections. Either dose of UFI significantly inhib- gene, fgf-4, and a genetic marker gene, bacterial lacZ encoding ited the tumor growth as well as the progression of micro- 3-gal.3 Transplantation of MKL-4 cells into the mammary fat metastasis into lymph nodes, lungs, liver, and brain. In pad of female nude mice produces rapid-growing tumors with- addition, enhanced progression of micrometastasis in all out supplementation of estradiol. In addition, whole-organ stain- explored organs by the tumor removal was significantly ing of excised organs from these nude mice for n-gal activity makes metastatic tumor cells blue, helping us to measure the degree of micrometastasis quantitatively. This staining revealed that MKL-4 cells spontaneously metastasized into the lymph nodes, lungs, liver, brain, and bone (bone metastasis was ob- Received 7/22/96; revised 12/I 1/96; accepted 2/4/97. served for the first time in this study). This metastasis model The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked should be useful for evaluating the inhibitory effect of certain advertisement in accordance with 18 U.S.C. Section 1734 solely to agents on metastatic activity (6, 7). Our previous experiment indicate this fact. using this model revealed that a potent antiangiogenic agent, I This work was supported by a grant from the Ministry of Education, TNP-470, clearly inhibits angiogenic activity, tumor growth, Science, Sports and Culture of Japan, by Research Project Grant 7-301 from Kawasaki Medical School (J. K., H. So.), and by NIH Grant 1P50CA58185 (R. B. D.). This article was presented in part at the 32nd Annual Meeting of the American Association of Clinical Oncology, Philadelphia, PA.

2 To whom requests for reprints should be addressed. Phone: 8 1-86- 3 The abbreviations used are: a-gal, -galactosidase; 5-Ri, 5-fluorou- 462-1111; Fax: 81-86-462-1199. racil; PD-ECGF, platelet-derived endotheial growth factor.

Downloaded from clincancerres.aacrjournals.org on September 30, 2021. © 1997 American Association for Cancer Research. 654 Inhibition of Progession of Micrometastasis by liFT

and spontaneous metastasis into the lymph nodes and distant degree of micrometastasis using a dissecting microscope. The organs (8). weights of the excised primary tumors were measured. 5-Ri is a widely used for the treatment of Experiment 2. Twenty nude mice were given injections various cancers. Tegafur is a of 5-Hi which is mainly of MKL-4 cells. Because the results of experiment 1 suggested converted to 5-Hi by microsomal P450 enzymes in the liver (9). that micrometastases may occur 3 weeks after the cell injections, Fujii and colleagues (10-12) found that the coadministration of transplanted MKL-4 tumors were resected in an aseptic condi- uracil and tegafur at a molar ratio of uracil:tegafur of 4:1 tion under ether anesthesia 3 weeks after the injections in the enhanced the concentration of 5-FU in the tumor and produced tumor removal group (10 mice). In the control group (10 mice), maximal antitumor activity in animal model systems. This no surgical maneuver was carried out. All of the mice were mixed compound, UFT (Taiho Pharmaceutical Co. Ltd., Tokyo, sacrificed 7 weeks after the injections. The right axillary lymph Japan), has been widely used in the treatment of breast, gastro- node, distal lymph nodes (contralateral axillary or bilateral intestinal, and head and neck cancers in Japan (13, 14). Because inguinal lymph nodes), lungs, liver, brain, and lumbar vertebral liFT is administered p.o., well tolerated, and devoid of severe bone were excised, stained for 3-gal activity, and observed. The neutropenia, it may provide a better quality of life and cost weights of the excised primary tumors were measured. benefit for patients with advanced cancer. Clinical and experi- Experiment 3. Thirty nude mice were given injections of mental studies of UFT in the treatment ofcolorectal, gastric, and MKL-4 cells. In the treatment groups (10 mice in each group), breast cancers are underway in Western countries (15-22). Very 15 or 20 mg/kg UFF were given p.o. to the mice six times a recently, a pharmacokinetic study showed that p.o. UFT gener- week from 3 to 7 weeks after the injections. The given volume ates a higher peak level of 5-Ri than can be achieved with of the Ufl’ solution was 10 mI/kg for either dose. In the control protracted i.v. 5-Ri infusion (23). Although liFT has also been group (10 mice), the same volume of the vehicle was given in used in the postoperative adjuvant setting for several cancers in the same manner. All of the mice were sacrificed 7 weeks after Japan (24-27), the scientific basis for postoperative UFf ad- the injections. Weights of the excised primary tumors and mice ministration in reducing recurrence and the mortality of cancer were measured. The lymph nodes and distant organs were patients is still unclear. Therefore, we decided to establish a new excised, stained for 3-gal activity, and observed. postoperative metastasis model and to clarify the usefulness of Experiment 4. Thirty nude mice were given injections of postoperative l1FT administration in this model. MKL-4 cells. In both groups as described below, transplanted Miu-i tumors were resected 3 weeks after the injections. In the treatment groups (10 mice in each group), 15 or 20 mg/kg UFF MATERIALS AND METhODS were given p.o. to the mice six times a week from 3 to 7 weeks Agents and Animals after the injections. In the control group (10 mice), the same Uracil and tegafur, provided by Taiho Pharmaceutical Co. volume of the vehicle was given in the same manner. All of the Ltd., were mixed (uracil:tegafur molar ratio of 4:1) and dis- mice were sacrificed 7 weeks after the injections. The weights of solved in 0.5% (w/v) carboxymethyl cellulose at a final tegafur the mice and right axillary lymph nodes were measured. Then, concentration of 1.5 or 2.0 mg/mi. The given dose (15 or 20 the lymph nodes and distant organs were excised, stained for mg/kg) of tegafur was expressed as that of UFT. All reagents 3-gal activity, and observed. used in the whole-organ staining for 3-gal activity described All experimental protocols in this study were approved by below were purchased from Sigma Chemical Co. (St. Louis, the Animal Care and Use Committee of Kawasaki Medical MO). The reagents used in culture were purchased as follows: School. Iscove’s modified Dulbecco’s medium from Life Technologies, Inc. (Tokyo, Japan), fetal bovine serum from ICN Biochemicals Whole-Organ Staining for 3-ga1 Activity Japan (Osaka, Japan), and trypsin from Difco Laboratories The excised organs from the sacrificed nude mice were cut (Detroit, MI). Female BALB/c-nu/nu mice (4-week old) were into two pieces except for lungs and immediately fixed for 2 h purchased from CLEA Japan (Tokyo, Japan). at room temperature with 2% (v/v) formalydehyde-0.2% (v/v) glutaraldehyde in PBS. The samples were then incubated with 1 Experimental Procedure mg/mi 5-bromo-4-chloro-3-indoyl-3-D-galactopyranoside, 5 The four consecutive experimental protocols were as fol- mM potassium ferricyanide, 5 mM potassium ferrocyanide, lows. 0.02% (v/v) NP4O, and 2 mM MgCl2 in PBS at 4#{176}Covernight. Experiment 1. Semiconfluent MKL-4 cells growing in Cut surfaces of the organs or whole lungs were observed and Iscove’s modified Dulbecco’s medium supplemented with 10% microphotographs were taken with an Olympus SZH dissecting fetal bovine serum at 37#{176}Cin a 5% Co2-air atmosphere were microscope (Olympus, Tokyo, Japan). The degrees of microme- trypsinized, harvested, and counted in a hemocytometer using tastasis in each organ were defined as follows: grade 0, no trypan blue exclusion. Approximately 1 X l0 viable cells/0.l metastasis observed; grade 1, 1-5 microscopic metastatic foci ml of saline were injected into the right upper mammary fat pad observed; grade 2, 6-10 microscopic metastatic foci observed; (a single injection/mouse) of 4-week-old female athymic nude grade 3, more than 10 microscopic metastatic foci observed; and mice. In this first experiment, 42 nude mice were given injec- grade 4, macroscopic metastasis (approximately larger than 3 tions of MKL-4 cells. Seven mice were sacrificed by a cervical mm) observed. Representative blue-stained metastatic foci are dislocation every week from 2 to 7 weeks after the cell injec- shown in Fig. 1. All of the samples were observed and the tions. The right axillary lymph node and lungs were excised grading of metastasis was performed by one of the authors from each mouse and stained for 3-gal activity to measure the (M. N.) in a blinded manner. Because the sizes of microscopic

Downloaded from clincancerres.aacrjournals.org on September 30, 2021. © 1997 American Association for Cancer Research. Clinical Cancer Research 655

and that these micrometastases may progress as time passes and as the primary tumors grow. Effect of Tumor Removal on the Progression of Micro-

metastasis. On the basis of the data of experiment I , trans- planted MKL-4 tumors were resected 3 weeks after the cell injections in the tumor removal group. The weight of the re- sected tumors was 0.15 ± 0.04 g (mean ± SD) in this group. In the control group, the weight of the tumors 7 weeks after the

injections was 1.20 ± 0.33 g. As shown in Table 1 , the degree of micrometastasis into the axillary lymph node, distant lymph nodes, or bone was significantly promoted by the removal of primary tumors. Although the degree of micrometastasis into the lungs, liver, or brain in the tumor removal group was slightly higher than that in the control group, the difference was not statistically significant. These findings suggest that tumor re- moval may enhance the progression of micrometastasis existing before the tumor removal. Effect of UFT on Tumor Growth and Progression of Micrometastasis. p.o. administration of either I 5 or 20 mg/kg UFT for 4 weeks from 3 weeks after the cell injections significantly reduced the weight of the primary tumors (P < 0.01 in each comparison to the control group). Neither dose of UFT affected the body weight of the mice (Table 2). Moreover, this treatment inhibited the progression of micro- metastasis in the tumor-bearing mice. The degree of micro- metastasis into the distant lymph nodes (for the 20 mg/kg- treatment group alone), lungs, liver, or brain was significantly reduced by the treatment with either dose of

Fig. I Blue-stained metastatic foci in a vertebral bone or bone marrow UFT. Micrometastasis into the axillary lymph node or bone (A, grade 2, X20) and into an axillary lymph node (B, grade 4, X20) was also slightly reduced by the treatment, but this difference after the tumor removal. The cut surface of each organ was stained for was not statistically significant (Table 2). These findings 3-gal activity and observed with a dissecting microscope. suggest that the p.o. administration of either 15 or 20 mg/kg UFT has a large enough potential to inhibit both the growth of primary tumors and the progression of both lymphatic and metastatic foci in the organs varied too greatly to be quantified, hematogenous micrometastases in this model. their size was not taken into account for the grading system. Effect of UFT on the Progression of Micrometasta.sis after Tumor Removal. On the basis of the data of experi- Statistical Analysis ments 2 and 3, 15 or 20 mg/kg UFT were administered p.o. to The incidence differences between the control group and the mice in which the primary tumors were resected 3 weeks the treatment group in the degree of micrometastasis in each after the cell injections. The degree of micrometastasis into each organ was evaluated using the Wilcoxon two-sample test. The explored organ was significantly reduced by the treatment with weights of the tumors, lymph nodes, and mice of the two groups either dose of UFT (Table 3). In addition, the weight of the were compared using Student’s t test. Values for P < 0.05 were axillary lymph nodes in the UFT treatment groups (mean ± SD, considered to be significant. 7. 1 ± 3. 1 mg for the 15-mg/kg group and 6.9 ± 3. 1 mg for the 20-mg/kg group) was significantly smaller than that in the tumor RESULTS removal-alone group (24.8 ± 7.8 mg; P < 0.01 in each corn- Timing of Occurrence of Micrometastasis. As shown panson). Again, no difference between the treatment and control in Fig. 2, micrometastasis into the right axillary lymph node or groups was seen in the body weight ofthe mice. Interestingly, in lungs was detected 3 weeks after the cell injections. Grade 1 1 and 2 mice, respectively, of the 10 mice treated with 15 and 20 micrometastasis into the lymph node and lungs was already mg/kg UFT, no micrometastasis was observed in any explored detected in 43% and 29% of the mice, respectively, 3 weeks organs. This inhibitory effect of UFT on the progression of after the injections (a mean tumor weight of 0. 10 g). The micrometastasis in tumor-resected mice seemed to he more frequency, degree, and size of micrometastasis gradually in- obvious than that in the tumor-bearing mice of experiment 3. creased, and all of the mice had microscopic and/or macroscopic These findings suggest that the enhanced progression of micro- metastases into the lymph node or lungs 7 weeks after the metastasis by the removal of primary tumors may be effectively injections. These findings suggest that lymphatic and hematog- inhibited by the postsurgical administration of UFT in this enous micrometastases may occur 3 weeks after the injections model.

Downloaded from clincancerres.aacrjournals.org on September 30, 2021. © 1997 American Association for Cancer Research. 656 Inhibition of Progession of Micrometastasis by UFF

0.6 100

‘a a, (a

Ca a, E >, C Ca Fig. 2 The growth curve of MKL-4 transplanted

) 0.3 tumors and the relationship between the timing of sacrifice of the mice and the frequency of micro- metastases in the axillary lymph node or lungs. #{149}, mean tumor weight. Bars, SD. 0 and i, percent- age of mice who are micrometastasis positive in the axillary lymph node and lungs, respectively.

50 0 0 2 3 4 5 6 7

Weeks after the cell injections

Table 1 Removal of MKL-4 transplanted tumors promoted the observe how these agents inhibit the progression of microme- progression of spontaneous micrometastases into lymph nodes and tastasis in these patients. This is also true in experimental animal distant organs in nude mice models. We recently developed a new spontaneous metastasis Grade of metastasis” model in nude mice using the MCF-7 human breast cancer cell Organ Tumor removal 0 1 2 3 4 line cotransfected with fgf-4 and lacZ. This model provided us with a quantitative measurement of micrometastasis in both Axillary lymph nodes No 2” 6 2 0 0 Yesc 0 4 6 0 0 lymph nodes and distant organs (6, 7). Therefore, we decided to develop a new postsurgical metastasis model using this animal Distant lymph nodes No 9 1 0 0 0 Yesc 4 5 1 0 0 model. First, we studied when micrometastasis occurs in the Lungs No 6 3 1 0 0 Yes 4 1 4 I 0 MKL-4 metastasis model. The results of experiment 1 mdi- cated that both lymphatic and hematogenous micrometastases Liver No 4 3 3 0 0 Yes 4 1 4 1 0 occur 3 weeks after the cell injections (Fig. 2). Similar Brain No 7 2 1 0 0 findings were also made in our previous study (7). In addi- Yes 5 2 3 0 0 tion, the frequency, degree, and size of micrometastasis in- Bone No 6 4 0 0 0 creased as time passed and as the primary tumor grew (not Yes” 0 2 7 1 0 shown in detail). These findings suggest that micrometastasis

a The grade of micrometastasis in each organ was defined as may occur and progress from 3 weeks onward after the described in “Materials and Methods.” injections. Therefore, we next investigated whether or not b The number of mice with a certain grade of metastasis in the removal of the primary tumors 3 weeks after the injections explored organ. Ten mice were tested in each group. promotes the progression of micrometastasis. As expected, C Tumor removal significantly promoted the progression of micro- metastasis: P < 0.05. the tumor removal significantly enhanced the progression of d Tumor removal significantly promoted the progression of micro- micrometastasis into both lymph nodes and distant organs metastasis: P < 0.01. (Table 1). It has been observed that the removal of primary tumors promotes the progression of secondary sites, i.e., micrometastases, in some experimental animal models (28- 33). Recently, an antiangiogenic factor, angiostatin secreted DISCUSSION from the primary tumors, was reported to be one of the most Postsurgical adjuvant have been intro- likely candidates to cause this phenomenon (34, 35). As our duced into the treatment of many malignancies. All agents used purpose in this study was not to elucidate the molecular in the postsurgical adjuvant setting have already been proven to mechanisms of such a phenomenon, the expression of an- be effective in the treatment of advanced malignancies. The giostatin in the primary tumors and the effect of the tumor antitumor effect of these agents has been thought to lead to the removal on the degree of neovascularization and apoptosis in inhibition of growth of micrometastasis from malignancies and the secondary sites was not studied. Otherwise, our primary to delay or decrease the occurrence of clinically detectable purpose was accomplished because a new postsurgical me- recurrences. As expected, many clinical trials after the surgical tastasis model in which micrometastasis can be measured removal of primary breast cancer have demonstrated that some quantitatively after tumor removal was established. antitumor agents improve disease-free survival and/or the over- Interestingly, micrometastasis into bone or bone marrow all survival of the patients (1-3). However, it is difficult to was frequently observed and its progression was promoted by

Downloaded from clincancerres.aacrjournals.org on September 30, 2021. © 1997 American Association for Cancer Research. Clinical Cancer Research 657

Table 3 Antimetastatic effect of UFT after the removal of MKL-4 Table 2 Antiproliferative and antimetastatic effects of UFT on MKL-4 transplanted tumors in nude mice transplanted tumors in nude mice

Antiproliferative effect Grade of metastasis” Dose of liFT Dose of UFF No. of Tumor weight Tumor” Body weight” (mg/kg) Organ 0 1 2 3 4 (mg/kg) mice (g) (%) (g) No Axillary lymph nodes 0” 2 3 2 3 No 10 1.01 ± 0.39’ 21.6 ± 33C 15C 6 4 0 0 0 15 10 0.20 ± 0.06” 19.9 23.0 ± 1.4 20’ 8 2000 20 10 0.16 ± 0d 15.9 22.7 ± 1.2 No Distant lymph nodes 6 3 1 0 0 Antimetastatic effect 10 0 0 0 0 Grade of metastasise 20” 10 0 0 0 0 Dose of UFT No Lungs 0 4 3 3 0 0 1 2 3 4 (mg/kg) Organ 15’ 7 3 0 0 0 No Axillary lymph nodes I 4 3 0 0 20’ 8 2 0 0 0 15 4 3 3 0 0 No Liver 1 4 4 1 0 20 7 2 1 0 0 l5C 7 3 0 0 0 No Distant lymph nodes 6 4 0 0 0 20’ 10 0 0 0 0 15 9 1 0 0 0 No Brain 2 3 5 0 0 20g 10 0 0 0 0 l5C 7 3 0 0 0 No Lungs 2 5 3 0 0 20’ 9 1 0 0 0 7 3 0 0 0 No Bone 0 2 7 1 0 20” 8 2 0 0 0 l5C 6 4 0 0 0 No Liver 2 5 3 0 0 20’ 9 1 0 0 0 lsg 7 3 0 0 0 a The grade of micrometastasis in each organ was defined as 20g 7 3 0 0 0 described in “Materials and Methods.” No Brain 2 6 2 0 0 b The number of mice with a certain grade of metastasis in the l5’ 8 2 0 0 0 explored organ. Ten mice were tested in each group.

20” 8 2 0 0 0 C The p.o. administration of liFT significantly inhibited the pro- gression of micrometastasis after tumor removal in comparison to that in No Bone 6 4 0 0 0 the control group: P < 0.01. 15 8 2 0 0 0 d The p.o. administration of UFT significantly inhibited the pro- 20 8 2 0 0 0 gression of micrometastasis after tumor removal in comparison to that in a Treated versus control. the control group: P < 0.05. b The body weights of mice were measured at autopsy after the primary tumors were excised. cMean ± SD. d The tumor weight was significantly reduced by p.o. administra- tion of liFT: P < 0.01. tasis model may be useful not only for studying the mechanisms e The grade of micrometastasis in each organ was defined as involved in the development of bone metastasis but also for described in “Materials and Methods.” investigating new strategies to inhibit the progression of bone 1The number of mice with a certain grade of metastasis in the explored organ. Ten mice were tested in each group. metastasis. g The p.o. administration of liFT significantly inhibited the pro- p.o. administration of antitumor agents, such as tegafur or gression of micrometastasis in comparison to that in the control group: tiFF, for the treatment of breast cancer and gastrointestinal P < 0.05. cancer is common in Japan (13, 14). These agents have also h The p.o. administration of liFT significantly inhibited the pro- been used in postsurgical adjuvant settings. Recently, liFT has gression of micrometastasis in comparison to that in the control group: P < 0.01. been used with leucovorin for the treatment of advanced cob- rectal and gastric cancer in Western countries because of its fewer adverse effects and comparative antitumor effect with i.v. 5-FU infusion (17, 19-21). In addition, combined use of UFT tumor removal in this study (Fig. 1). In addition, multiple with other chemotherapeutic agents has been investigated in macroscopic metastases into the lumbar vertebral bones were clinical phase studies for the treatment of gastric cancer (36, 37). observed 1 2 and 24 weeks after the tumor removal.4 In our In the present study, on the basis of our preliminary study (38), previous study, no bone metastasis was observed in the femur of relatively low doses of UFF were administered p.o. Either 15 or mice bearing MKL-4 transplanted tumors (7). In contrast, mi- 20 mg/kg UFF significantly inhibited the growth of MKL-4 crometastasis was frequently observed in the lumbar vertebral transplanted tumors without affecting the body weight of the bone of the mice. Although bone is one of the most common mice. The progression of micrometastasis was also inhibited by metastasic sites in human breast cancer, stable spontaneous either dose of liFT. Surprisingly, either dose of UFF clearly metastasis into bone in a nude mouse model using human breast inhibited the enhanced progression of micrometastasis by tumor cancer cells has not been reported previously. This bone metas- removal. It is conceivable that the enhanced proliferation or diminished apoptosis of tumor cells by tumor removal may make the tumor cells more sensitive to UFF. In addition, tegafur is known to be one of the substrates of thymidine phosphorylase

4 Unpublished data. (39). Recently, an angiogenic factor, PD-ECGF has been sug-

Downloaded from clincancerres.aacrjournals.org on September 30, 2021. © 1997 American Association for Cancer Research. 658 Inhibition of Progession of Micrometastasis by UFT

gested to be identical to thymidine phosphorylase (40). PD- 11. Taguchi, T., Nakao, Y., Fujii, S., and Shirasaka, T. Determination ECGF has been reported to increase many types of malignant of 5- levels in tumors, blood and other tissues. Cancer Chemother., 5: 1167-1172, 1978. tumors (41). Therefore, there is a possibility that tegafur might 12. Fujii, S., Kitano, S., Ikenaka, K., and Shirasaka, T. Effect of influence the activity of PD-ECGF and tumor angiogenesis. coadministration of uracil or cytosine on the antitumor activity of Further investigation is needed to elucidate the action mecha- clinical doses of l-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-flu- nisms of UFT on the progression of micrometastasis after tumor orouracil in rodents. Gann, 70: 209-214, 1979. removal. However, to the best of our knowledge, this is the first 13. Ota, K., Taguchi, T., and Kirnura, K. Report on nationwide pooled demonstration that p.o. administration of a 5-Ri derivative data and cohort investigation in UFT phase II study. Cancer Chemother. Pharmacol., 22: 333-338, 1988. inhibits the progression of micrometastasis after surgery. To develop a new postoperative metastasis model in which 14. Kurihara, M. Clinical experience with UFF in Japan. Adv. Exp. Med. Biol., 339: 243-251, 1993. the early events of metastasis, i.e. , micrometastases, can be 15. Malik, S. T. A., Talbot, D., Clarke, P. I., Osborne, R., Reznek, R., evaluated, we investigated the timing of occurrence of micro- Wringley, P. F. M., and Slevin, M. L. Phase II trial of liFT in advanced metastasis and the effects of the removal of primary tumors on colorectal and gastric cancer. Br. J. Cancer, 62: 1023-1025, 1990. the progression of micrometastasis in the MKL-4 metastasis 16. Ho, D. H., Civington, W. P., Pazdur, R., Brown N. S., Kuritani, J., model. Tumor removal at the time when micrometastasis oc- Newman, R. A., Raber M. N., and Krakoff, I. H. Clinical pharmacology curred significantly enhanced the progression of micrometasta- of combined oral uracil and ftorafur. Drug Metab. Dispos., 20: 936- 940, 1992. sis. In addition, the p.o. administration of liFT clearly inhibited 17. Gonzalezbaron, M., Feliu, J., Ordonez, A., Colmenarejo, A., the progression of micrometastasis. This newly developed post- Espinosa, E., Zamora, P., Gandara, I. D., and Jalon, J. I. Phase I study surgical metastasis model may be useful in the evaluation of of UFF plus leucovorin in advanced : a double mod- agents used in the postoperative adjuvant setting as well as in ulation proposal. Anticancer Res., 13: 759-762, 1993. the development of new strategies against the progression of 18. Daniels, M., Diaz-Rubio, E., Guillem, V., Montero, J. M., Garcia- micrometastasis after surgery. Conde, J., Estape, J., Martin M., Herranz, C., Ordenez, A., and Galan, A. Phase II trial of UFT activity in pretreated breast cancer patients. Jpn. J. Clin. Oncol., 23: 363-365, 1993. REFERENCES 19. Pazdur, R., Lassere, Y., Rhodes, V., Ajani, J. A., Sugarman, S. M., Pan, Y. Z., Jones, D. V., Jr., Markowitz, A. B., Abbruzzese, J. L., 1. Early Breast Cancer Trialists’ Collaborative Group. Systemic treat- Bready, B., and Levin, B. Phase II trial of uracil and tegafur plus oral ment of early breast cancer by hormonal, cytotoxic, or immune therapy. leucovorin: an effective oral regimen in the treatment of metastatic 133 randomised trials involving 31,000 recurrences and 24,000 deaths colorectal carcinoma. J. Clin. Oncol., 12: 2296-2300, 1994. among 75,000 women (Part 1). Lancet, 339: 1-15, 1992. 20. Sanchiz, F., and Milla, A. Tegafur.uracil (UFT) plus folinic acid in 2. Early Breast Cancer Trialists’ Collaborative Group. Systemic treat- advanced rectal cancer. Jpn. J. Clin. Oncol., 24: 322-326, 1994. ment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths 21. Saltz, L. B., Leichman, C. G., Young, C. W., Muggia, F. M., Conti, among 75,000 women (Part 2). Lancet, 339: 71-85, 1992. J. A., Spiess, T., Jeffers, S., and Leichman, L. P. A fixed-ratio combi- nation of uracil and ftorafur (UFT) with low dose leucovorin. Cancer 3. Perren, T. J. Adjuvant therapy for operable breast cancer; more (Phila.), 75: 782-785, 1995. answers, new questions. Br. J. Cancer, 71: 1 142-1 144, 1995. 22. Cao, S., Frank, C., Shirasaka, T., and Rustum, Y. M. 5-Fluorouracil 4. Sledge, G. W., Jr., Qulali, M., Goulet, R., Bone, E. A., and Fife, R. prodrug: role of anabolic and catabolic pathway modulation in therapy Effect of matrix metalloproteinase inhibitor Batimastat on breast cancer of colorectal cancer. Clin. Cancer Res., 1: 839-845, 1995. regrowth and metastasis in athymic mice. J. Nati. Cancer Inst., 87: 23. Puzdar, R., Covingotn, W. P., Brown, N. S., Lassere, Y., Diaz- 1546-1550, 1995. Canton, E., and Ho, D. H. Comparative steady state of 5. Price, J. E., Polyzos, A., Zhang, R. D., and Daniels, L. M. Tumon- oral liFT versus protracted intravenous 5-fluorouracil (Ri) (Abstract). genicity and metastasis of human breast carcinoma cell lines in nude Proc. Am. Soc. Clin. Oncol., 15: 474, 1996. mice. Cancer Res., 50: 717-721, 1990. 24. Macham, Y., Watanabe, A., Kakeji, Y., Baba, H., Kohnoe, S., and 6. McLeskey, S. W., Kurebayashi, J., Honig, S. F., Ziebel, J., Lippman, Sugimachi, K. Postgastrectomy prescription of and UFT M. E., and Kern, F. G. Fibroblast growth factor 4 transfection of MCF-7 for patients with stage IV gastric carcinoma. Am. J. Surg., 160: 242- cells produces cell lines that are tumorigenic and metastatic in ovariec- 244, 1990. tomized or tamoxifen-treated athymic nude mice. Cancer Res., 53: 25. The Study Group of Adjuvant Chemotherapy for 2168-2177, 1993. (Chubu, Japan). A randomized trial of postoperative adjuvant chemo- 7. Kurebayashi, J., McLeskey, S. W., Johnson, M. D., Lippman, M. E., therapy in non-small cell lung cancer (the second cooperative study). Dickson, R. B., and Kern, F. G. Quantitative demonstration of sponta- Eur. J. Surg. Oncol., 21: 69-77, 1995. neous metastasis by MCF-7 human breast cancer cells cotransfected 26. Arima, S., Ohsato, K., Hisatsugu, T., and Shimura, H. Multicentre with fibroblast growth factor 4 and lacZ. Cancer Res., 53: 2178-2187, randomised study of adjuvant chemotherapy with mitomycin C and 1993. tegafur or tegafur-uracil in gastric cancer. Eur. J. Surg., 160: 227-232, 8. Kurebayashi, J., Kurosumi, M., Dickson, R. B., and Sonoo, H. 1994. Angiogenesis inhibitor O-(chboroacetyl-carbamoyl)fumagillol (TNP- 27. Wada, H., Hitomi, S., and Teramatsu, T. Postoperative non-small 470) inhibits tumor angiogenesis, growth and spontaneous metastasis of cell lung cancer: a prospective randomized trial of (P)-vin- MKL-4 human breast cancer cells in female athymic nude mice. Breast desine (VDS)-UFT vs liFT alone vs control (Abstract). Proc. Am. Soc. Cancer, 1: 109-115, 1994. Clin. Oncol., 13: 328, 1994. 9. bide, H., Akiyoshi, H., Minato, Y., Okuda, H., and Fujii, S. Corn- 28. Schauen, W. E. An experimental study of postoperative tumor parative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil metastases. I. Growth of pulmonary metastases following total removal and 5-fluorouracil. Gann, 68: 553-560, 1977. of primary leg tumor. Cancer (Phila.), 11: 455-459, 1958. 10. Fujii, S., Ikenaka, K., Fukushirna, M., and Shirasaka, T. Effect of 29. DeWys, W. D. Studies correlating the growth rate of a tumor and its uracil and its derivatives on antitumor activity of 5-fluorouracil and rnetastases and providing evidence for tumor-related systemic growth- 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann, 69: 763-772, 1978. retarding factors. Cancer Res., 32: 374-379, 1972.

Downloaded from clincancerres.aacrjournals.org on September 30, 2021. © 1997 American Association for Cancer Research. Clinical Cancer Research 659

30. Gorelik, E., Segal, S., and Feldman, M. Growth of a local tumor otherapy for high-grade advanced gastric cancer. World J. Surg., 17: exerts a specific inhibitory effect on progression of lung metastases. Int. 256-261, 1993. J. Cancer, 21: 617-625, 1978. 37. Hayakawa, M., Morise, K., Chin, K., Sugihara, M., Morooka, Y., 31. Fisher, B., Gunduz, N., and Saffer, E. A. Influence of the interval Maeda, H., Hattori, T., and Saito, H. Combination chemotherapy with between primary tumor removal and chemotherapy on kinetics and tegafur.uracil (Ufl’), , adriamycin and cisplatinum (UFT- growth of metastases. Cancer Res., 43: 1488-1492, 1983. EAP) for advanced gastric cancer. Jpn. J. Clin. Oncol., 24: 282-288, 1994. 32. Fisher, B., Gunduz, N., Coyle, J., Rudock, C., and Saffer, E. Presence of a growth-stimulating factor in serum following primary 38. Kurebayashi, J., and Sonoo, H. Antiproliferative and antimetastatic effects of liFT on MKL-4 human breast cancer cells transplanted into tumor removal in mice. Cancer Res., 49: 1996-2001, 1989. nude mice. Jpn. J. Cancer Chemother., 22: 665-670, 1995. 33. O’Reilly, M. S., Rosenthal, R., Sage, E. H., Smith, S., Holmgren, 39. Kono, A., Hara, Y., and Mastushima, Y. Enzymatic formation of L., Moses. M., Shing, Y., and Folkman, J. The suppression of tumor 5-fluorouracil from l-(tetrahydro-2-furanyl)-5-fluorouracil (tegafur) in metastases by a primary tumor. Surg. Forum, 44: 474-476, 1993. human tumor tissues. Chem. & Pharm. Bull. (Tokyo), 29: 1486-1488, 34. O’Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, 1981. R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, 40. Sumizawa, T., Furukawa, T., Haraguchi, M., Yoshirnura, A., J. Angiostatin: a novel angiogenesis inhibitor that mediates the Takeyasu, A., Ishizawa, M., Yamada, Y., and Akiyama, S. Thymidine suppression of metastases by a Lewis lung carcinoma. Cell, 79: phosphorylase activity associated with platelet-derived endothelial cell 315-328, 1994. growth factor. J. Biochem., 114: 9-14, 1993. 35. Holmgren, L., O’Reilly, M. S., and Folkman, J. Dormancy of 41. Yoshimura, A., Kuwazuru, Y., Furukawa, T., Yoshida, H., Yamada, micrornetastases: balanced proliferation and apoptosis in the presence of K., and Akiyama, S. Purification and tissue distribution of human angiogenesis suppression. Nat. Med., 1: 149-153, 1995. thymidine phosphorylase; high expression in lymphocytes, reticulocytes 36. Yonernura, Y., Sawa, T., and Kinoshoshita, K. Neoadjuvant chem- and tumors. Biochirn. Biophys. Acta, 1034: 107-113, 1990.

Downloaded from clincancerres.aacrjournals.org on September 30, 2021. © 1997 American Association for Cancer Research. Postsurgical oral administration of uracil and tegafur inhibits progression of micrometastasis of human breast cancer cells in nude mice.

J Kurebayashi, M Nukatsuka, A Fujioka, et al.

Clin Cancer Res 1997;3:653-659.

Updated version Access the most recent version of this article at: http://clincancerres.aacrjournals.org/content/3/5/653

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and To order reprints of this article or to subscribe to the journal, contact the AACR Publications Subscriptions Department at [email protected].

Permissions To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/3/5/653. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.

Downloaded from clincancerres.aacrjournals.org on September 30, 2021. © 1997 American Association for Cancer Research.